Japan's mainstay next-generation H3 rocket, developed by Mitsubishi Heavy Industries Ltd. and the Japan Aerospace Exploration Agency (JAXA), is now in the final stages of preparation for its first launch, to be conducted by the end of March 2022. By keeping the launch cost of each rocket at half the conventional price, at ¥5 billion, developers aim to attract a wide range of commercial demand, including launching satellites for organizations overseas. But with foreign companies such as U.S.-based SpaceX ahead of the game in offering low-cost rocket transport, some are asking whether there are opportunities for Japanese rockets to compete against their overseas rivals. On March 17, the first test model of the H3 rocket made its debut at the launch site at the Tanegashima Space Center in Kagoshima Prefecture, as it was assembled, received fuels and underwent checking procedures down to the countdown just before the rocket launch. JAXA celebrated the milestone, saying it had overcome one of the "biggest mountains."
Artificial intelligence (AI) has sped up the process of detecting flooded buildings immediately after a large-scale flood, allowing emergency personnel to direct their efforts efficiently. Now, a research group from Tohoku University has created a machine learning (ML) model that uses news media photos to identify flooded buildings accurately within 24 hours of the disaster. Their research was published in the journal Remote Sensing on April 5, 2021. "Our model demonstrates how the rapid reporting of news media can speed up and increase the accuracy of damage mapping activities, accelerating disaster relief and response decisions, said Shunichi Koshimura of Tohoku University's International Research Institute of Disaster Science and co-author of the study. ML and deep learning algorithms are tailored to classify objects through image analysis.
Forecasts by Application (Drug Discovery, Precision Medicine, Medical Imaging & Diagnostics, Research), by Technology (Machine Learning, Other Technologies), by Offering (Hardware, Software, Services), by Deployment (Cloud, On-Premises) AND Regional and Leading National Market Analysis PLUS Analysis of Leading AI Companies AND COVID-19 Recovery ScenariosNew York, April 15, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Artificial Intelligence (AI) in Pharmaceutical Market Report 2021-2031" - https://www.reportlinker.com/p06061831/?utm_source=GNW How Adoption of Artificial Intelligence Impacting Pharmaceutical Industry? The global pharmaceuticals industry is in the throes of transition, both clinical trials and regulatory approvals have been challenged by the proliferation of specialized drugs catering to smaller patient groups. In order to boost results in drug discovery, clinical trials, and research and development, the pharmaceutical and life sciences companies are switching to robotic process control, artificial intelligence and machine learning. All these factors are anticipated to propel demand for artificial intelligence in pharmaceutical across the globe. Artificial Intelligence Anticipated to Revolutionize Several Aspects of Pharmaceutical Industry The way drugs are made, prescribed and ingested today will be standardized by artificial intelligence. Many facets of the pharmaceuticals and life sciences industry will also be revolutionized but will not heal sickness or replace physicians. Understanding the main aim of artificial intelligence, which is to improve human capability and accomplishment instead of challenging it, would dispel much of the technology’s concerns and put out its excellent ability to serve humanity. Which Factors are Fueling AI in Pharmaceuticals Industry Growth? . Growing Complexity of Modern Pharmacology . Growing Demand for Viable Therapeutic Candidates . Improves Overall R&D Productivity . Concerns Associated with Rising Capital Requirements in Drug Discovery . Increasing Awareness Related to Artificial Intelligence Among Pharmaceutical Manufacturers Which Factors are Restraining Growth? . Lack of Skilled Professionals . Limited Availability of Datasets UNIQUE COVID-19 VARIATIONS- only available in this Visiongain report are dedicated analysis of 4 different rebound scenarios of how the market will develop - no matter how COVID-19 affects the economy. To access the data contained in this document please email email@example.com How do prominent players strengthen their position throughout the world? You must read this newly updated report if you are involved in this sector. The report from Visiongain shows you potential revenues up to 2031, evaluate information, trends, opportunities and business outlooks. Discover how to stay ahead Our 350+ page report provides 500+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing AI in Pharmaceuticals Market. See how to exploit the opportunities. Forecasts to 2031 and other analyses reveal the commercial prospects . In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares. . You find original analyses, with business outlooks and developments. . Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), SWOT Analysis, PEST Analysis, Porter’s Analysis, product profiles and commercial developments. Discover sales predictions for the world market and submarkets Application . Drug Discovery . Precision Medicine . Medical Imaging & Diagnostics . Research Technology . Machine Learning . Other Technologies Offering . Hardware . Software . Services Deployment . Cloud . On-Premises In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 13 leading national markets: By Region (Segmental Breakdown for All the Regions) . North America - U.S. - Canada . Europe - Germany - France - UK - Italy - Spain - Rest of Europe . Asia Pacific - China - Japan - India - Rest of Asia Pacific . RoW Need industry data? Please contact us today. Leading companies and the potential for market growth Overall world revenue for AI in Pharmaceuticals Market will surpass $xx billion in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead. Prospects for established firms and those seeking to enter the market- including company profiles for 16 of the major companies involved in the AI in Pharmaceuticals Market. Some of the companies profiled in this report include are Microsoft Corporation, NVIDIA Corporation, IBM Corporation, Alphabet Inc., Atomwise, Inc., Deep Genomics, Cloud Pharmaceuticals, Inc., Insilico Medicine, BenevolentAI, Exscientia, Biosymetrics, Euretos, Insitro, Cyclica, Biovista, and OWKIN, INC. Key Questions Answered by this Report . What is the current size of the overall global AI in Pharmaceuticals market? How much will this market be worth from 2021 to 2031? . What are the main drivers and restraints that will shape the overall AI in Pharmaceuticals market over the next ten years? . What are the main segments within the overall AI in Pharmaceuticals market? How much will each of these segments be worth for the period 2021 to 2031? How will the composition of the market change during that time, and why? . What factors will affect that industry and market over the next ten years? . What are the largest national markets for the world AI in Pharmaceuticals? What is their current status and how will they develop over the next ten years? What are their revenue potentials to 2031? . How will market shares of the leading national markets change by 2031, and which geographical region will lead the market in 2031? . Which are the leading companies and what are their activities, results, developments, and prospects? . What are the main trends that will affect the world AI in Pharmaceuticals market between 2021 and 2031? . What are the main strengths, weaknesses, opportunities, and threats for the market? . How will the global AI in Pharmaceuticals market evolve over the forecasted period, 2021 to 2031? . How will market shares of prominent national markets change from 2021, and which countries will lead the market in 2031, achieving highest revenues and fastest growth? Read the full report: https://www.reportlinker.com/p06061831/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
More networks, industries, and machines will be interconnected as 5G become more widely available, making security an even bigger challenge for businesses in Asia-Pacific. Along with this, they also will have to deal with the increased complexity of managing 5G infrastructures, including the use of network slicing. Beyond just providing consumers with faster data speeds, the emergence of 5G networks would see more industries and devices connected as enterprises tapped the lower latency the technology could deliver, said John Harrington, Nokia's senior vice president and head of Asia-Pacific Japan. The COVID-19 pandemic also had accelerated the digitalisation of physical industries such as energy and transport and their reliance on high-speed, digital connectivity, he said in a call with ZDNet. Stressing the need to safeguard key systems, Singapore will set up a panel comprising global experts to offer advice on operational technology (OT) cybersecurity and launches the country's cybersecurity blueprint that focuses on securing digital infrastructure and cyber activities.
As research involving transplanting lab-grown human'mini-brains' into animals to study neurological diseases continues to expand, experts warn the work with these brain organoids could result in a'Planet of the Apes' scenario. The concern is animals could develop humanized traits and start to behave similar to the intelligent apes of the popular science fiction story. The warning comes from a team at Kyoto University who released a paper highlighting a number of ethical implications that could arise with brain organoid research. Although many see brain organoids as a way to quickly develop disease treatments, others fear that because they are designed to mimic the real thing, they too may attain some form of consciousness. Experts warn the work with these brain organoids could result in a'Planet of the Apes' (pictured) scenario.
The system uses robots to conduct polymerase chain reaction, or PCR, tests, significantly reducing infection risks for technicians. "The system will reduce the burden on medical workers, who are becoming exhausted from measures aimed at preventing infections," especially as Japan braces for a fourth wave of COVID-19 cases, Hiroyasu Ito, a professor at the university, said. The system, developed by Kawasaki Heavy Industries Ltd., is housed in a container 2.5 meters wide and 12.2 meters long, and has 13 robotic arms. It conducts all the steps required to test samples for coronavirus infections without human intervention. The university is aiming to make it possible for the system to produce test results in just 80 minutes.
That's where Hitachi hopes to employ GlobalLogic's engineering know-how in manufacturing, energy and other sectors to expand further outside Japan, said Gajen Kandiah, chief executive of Hitachi Vantara, the firm's digital infrastructure segment. "Unfortunately, you only hear about a small group of companies that are maximizing data," he said. "You don't hear about the 99% that isn't." The Morning Download delivers daily insights and news on business technology from the CIO Journal team. Digital services and the data analytics that power them have been a competitive advantage for many companies during the pandemic, with global supply chains upended and employees and customers interacting virtually.
It's hoped that COVID-19 vaccines will be the silver bullet that eventually allows society to return to normal. But even an accelerated inoculation campaign is unlikely to have a major impact on what appears to be a growing fourth wave of infections in Tokyo, according to research by a Tsukuba University professor. Setsuya Kurahashi, a professor of systems management, conducted a simulation using artificial intelligence that looked at how the vaccine rollout would help prevent the spread of the coronavirus in Tokyo if new infections rise at the same pace as during the second wave last summer. Even if 70,000 vaccinations per day, or 0.5% of the capital's 14 million people, were given to Tokyoites -- with priority given to people age 60 and over -- the capital would still see a fourth wave of infections peaking at 1,610 new cases on May 14, the study showed. The study also showed a fifth wave is expected to peak at 640 cases on Aug. 31.
The enduring appeal of both Kong and Godzilla has to do with their simplicity. "King Kong," made in Hollywood, débuted in 1933; "Godzilla," produced in Japan, came out in 1954. Both films relied on a stark and clarified premise: fantastic monsters let loose in ordinary human reality, which, in the light of their presence, is revealed to be even more hideous than the monsters themselves. That symbolic power, rather than their physical power, is the source of their enduring appeal, and it's the fundamental element that "Godzilla vs. Kong," the new mashup, directed by Adam Wingard, stomps into oblivion. The film is garishly overloaded with splices and grafts from other movies, other genres, and other premises, including a mythical setting and an evil corporation.